Cristina Stefania Dumitru1, Amalia Raluca Ceausu2, Serban Comsa2, Marius Raica2. 1. Department of Microscopic Morphology/Histology, Angiogenesis Research Center, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania dcristinastefania@gmail.com. 2. Department of Microscopic Morphology/Histology, Angiogenesis Research Center, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Abstract
BACKGROUND/AIM: The aim of the study was to evaluate the correlation between the rate of proliferation and immunohistochemical expression of E-cadherin, and their predictive role in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Samples were collected from 50 patients with HNSCC, and the expression of Ki-67 and E-cadherin was evaluated by immunohisto-chemistry (IHC). Previously, samples were conventionally stained with haematoxylin and eosin for histological diagnosis and grade. RESULTS: High E-cadherin expression was predominantly associated with less differentiated tumours (p<0.5; p=0.0305). Also, we observed a significant correlation between Ki-67 expression in tumour cells and tumour grade (p=0.0245). A strong correlation was noticed between low E-cadherin expression, increased Ki-67-proliferation rate and advanced T2-T3 tumour stage (p=0.0242). CONCLUSION: In this study we showed that Ki-67 proliferation rate and E-cadherin expression are important features in patients with HNSCC. Therefore, higher Ki-67 index values correlate with loss of E-cadherin expression, which indicates a poorer prognosis. These aspects support the use of both Ki-67 and E-cadherin as prognostic markers in specimens from patients with HNSCC.
BACKGROUND/AIM: The aim of the study was to evaluate the correlation between the rate of proliferation and immunohistochemical expression of E-cadherin, and their predictive role in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: Samples were collected from 50 patients with HNSCC, and the expression of Ki-67 and E-cadherin was evaluated by immunohisto-chemistry (IHC). Previously, samples were conventionally stained with haematoxylin and eosin for histological diagnosis and grade. RESULTS: High E-cadherin expression was predominantly associated with less differentiated tumours (p<0.5; p=0.0305). Also, we observed a significant correlation between Ki-67 expression in tumour cells and tumour grade (p=0.0245). A strong correlation was noticed between low E-cadherin expression, increased Ki-67-proliferation rate and advanced T2-T3 tumour stage (p=0.0242). CONCLUSION: In this study we showed that Ki-67 proliferation rate and E-cadherin expression are important features in patients with HNSCC. Therefore, higher Ki-67 index values correlate with loss of E-cadherin expression, which indicates a poorer prognosis. These aspects support the use of both Ki-67 and E-cadherin as prognostic markers in specimens from patients with HNSCC.
Authors: Gabriella Szentkúti; Kornél Dános; Diána Brauswetter; Gergő Kiszner; Tibor Krenács; László Csákó; Gábor Répássy; László Tamás Journal: Pathol Oncol Res Date: 2014-12-31 Impact factor: 3.201
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: G Pannone; A Santoro; A Feola; P Bufo; P Papagerakis; L Lo Muzio; S Staibano; F Ionna; F Longo; R Franco; G Aquino; M Contaldo; S De Maria; R Serpico; A De Rosa; C Rubini; S Papagerakis; A Giovane; V Tombolini; A Giordano; M Caraglia; M Di Domenico Journal: Curr Cancer Drug Targets Date: 2014 Impact factor: 3.428
Authors: Frank Jacobsen; Jacob Kohsar; Florian Gebauer; Martina Kluth; Claudia Hube-Magg; Ronald Simon; Maximilian Bockhorn; Andrea Hinsch; Eike Burandt; Andreas M Lübke; Stefan Steurer; Michael Tachezy; Guido Sauter; Jacob R Izbicki; Wildemar Wilczak; Nathaniel Melling Journal: Oncotarget Date: 2020-03-24
Authors: Emiel Kop; Geertruida H de Bock; Maartje G Noordhuis; Lorian Slagter-Menkema; Bernard F A M van der Laan; Johannes A Langendijk; Ed Schuuring; Bert van der Vegt Journal: Clin Otolaryngol Date: 2019-11-05 Impact factor: 2.597